Literature DB >> 33269460

Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.

Christof Kaltenmeier1, Ibrahim Nassour1, Richard S Hoehn1, Sidrah Khan1, Alison Althans1, David A Geller1, Alessandro Paniccia1, Amer Zureikat1, Samer Tohme2.   

Abstract

AIM: To assess the predictors and influence of resection margins and the role of neoadjuvant and adjuvant therapy on survival for a national cohort of patients with resected pancreatic cancer.
METHODS: Using the National Cancer Data Base between 2004 and 2016, 56,532 patients were identified who underwent surgical resection for pancreatic adenocarcinoma. Univariate and multivariate models were employed to identify factors predicting R0/R1 resection and assess the impact on survival.
RESULTS: In total, 48,367 (85.6%) patients were found to have negative margins (R0) compared to 8165 (14.4%) who had microscopic residual tumor (R1). Factors predicting positive margin on univariate analysis included male gender, Medicare, advanced stage, moderately or poorly differentiated tumor, lymphovascular invasion, and tumors > 2 cm. Factors predicting R0 resection included receipt of neoadjuvant therapy and treatment at an Academic/Research Center. Following adjustment for other factors, margin status remained an independent predictor for overall survival (HR: 1.24; 95% CI 1.22-1.27, p < 0.001) (1-, 3-, and 5-year overall survival rates (R0: 77%, 37%, and 25% vs R1: 62%, 19%, and 10%).
CONCLUSIONS: A positive margin predicts a poorer survival than R0 resections regardless of stage and receipt of adjuvant therapy. Several modifiable factors significantly predict the likelihood of R0 resection including neoadjuvant treatment and treatment at Academic/Research Programs. Knowledge about these factors can help guide patient management by offering neoadjuvant treatment modalities at Academic as well as Community hospitals.

Entities:  

Keywords:  Margin status; pancreatic cancer; predictors of R1 resection; survival

Year:  2020        PMID: 33269460      PMCID: PMC8169716          DOI: 10.1007/s11605-020-04870-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

Review 1.  The role of neoadjuvant therapy in pancreatic cancer: a review.

Authors:  Suzanne Russo; John Ammori; Jennifer Eads; Jennifer Dorth
Journal:  Future Oncol       Date:  2016-02-01       Impact factor: 3.404

Review 2.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Redefining resection margin status in pancreatic cancer.

Authors:  Caroline S Verbeke; Krishna V Menon
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

4.  A Tale of Two Cancers: Traveling to Treat Pancreatic and Thyroid Cancer.

Authors:  Michael G White; Megan K Applewhite; Edwin L Kaplan; Peter Angelos; Dezheng Huo; Raymon H Grogan
Journal:  J Am Coll Surg       Date:  2017-05-01       Impact factor: 6.113

Review 5.  Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).

Authors:  Thomas Seufferlein; Thomas J Ettrich
Journal:  Transl Gastroenterol Hepatol       Date:  2019-03-27

6.  Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma.

Authors:  D Ansari; M Bauden; S Bergström; R Rylance; G Marko-Varga; R Andersson
Journal:  Br J Surg       Date:  2017-02-08       Impact factor: 6.939

Review 7.  Advances in surgery for pancreatic cancer.

Authors:  Alexandra W Acher; Josh Bleicher; Austin Cannon; Courtney Scaife
Journal:  J Gastrointest Oncol       Date:  2018-12

8.  The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.

Authors:  Paula Ghaneh; Jorg Kleeff; Christopher M Halloran; Michael Raraty; Richard Jackson; James Melling; Owain Jones; Daniel H Palmer; Trevor F Cox; Chloe J Smith; Derek A O'Reilly; Jakob R Izbicki; Andrew G Scarfe; Juan W Valle; Alexander C McDonald; Ross Carter; Niall C Tebbutt; David Goldstein; Robert Padbury; Jennifer Shannon; Christos Dervenis; Bengt Glimelius; Mark Deakin; Alan Anthoney; Markus M Lerch; Julia Mayerle; Attila Oláh; Charlotte L Rawcliffe; Fiona Campbell; Oliver Strobel; Markus W Büchler; John P Neoptolemos
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

9.  Improving pancreas surgery over time: Performance factors related to transition of care and patient volume.

Authors:  Jon Arne Søreide; Oddvar M Sandvik; Kjetil Søreide
Journal:  Int J Surg       Date:  2016-06-29       Impact factor: 6.071

Review 10.  Immunotherapy and Prevention of Pancreatic Cancer.

Authors:  Alexander H Morrison; Katelyn T Byrne; Robert H Vonderheide
Journal:  Trends Cancer       Date:  2018-04-30
View more
  5 in total

1.  Worldwide diffusion of robotic approach in general surgery.

Authors:  Rong Liu; Qu Liu; Zizheng Wang
Journal:  Updates Surg       Date:  2021-01-02

2.  Assessing the perioperative complications and outcomes of robotic pancreaticoduodenectomy using the National Cancer Database: is it ready for prime time?

Authors:  Hassan Aziz; Muhammad Khan; Sara Khan; Guillermo P Serra; Martin D Goodman; Yuri Genyk; Mohd Raashid Sheikh
Journal:  J Robot Surg       Date:  2021-08-16

3.  Feasibility of "cold" triangle robotic pancreatoduodenectomy.

Authors:  Emanuele F Kauffmann; Niccolò Napoli; Michael Ginesini; Cesare Gianfaldoni; Fabio Asta; Alice Salamone; Gabriella Amorese; Fabio Vistoli; Ugo Boggi
Journal:  Surg Endosc       Date:  2022-07-26       Impact factor: 3.453

Review 4.  Robotic pancreas surgery: an overview of history and update on technique, outcomes, and financials.

Authors:  Hussein H Khachfe; Joseph R Habib; Salem Al Harthi; Amal Suhool; Ali H Hallal; Faek R Jamali
Journal:  J Robot Surg       Date:  2021-08-06

5.  Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.

Authors:  Carl Stephan Leonhardt; Willem Niesen; Eva Kalkum; Rosa Klotz; Thomas Hank; Markus Wolfgang Büchler; Oliver Strobel; Pascal Probst
Journal:  BJS Open       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.